DuPont de Nemours (DD) Down 2.2% Since Last Earnings Report: Can It Rebound?
Werte in diesem Artikel
It has been about a month since the last earnings report for DuPont de Nemours (DD). Shares have lost about 2.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is DuPont de Nemours due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. DuPont's Q3 Earnings Top Estimates, Sales Up on Higher VolumesDuPont registered earnings from continuing operations of $1.13 per share in the third quarter of 2024, up from earnings of 62 cents per share in the year-ago quarter. Barring one-time items, earnings came in at $1.18 per share in the reported quarter, topping the Zacks Consensus Estimate of $1.04.DuPont logged net sales of $3.19 billion, marking a 4% year-over-year increase. It missed the Zacks Consensus Estimate of $3.20 billion. Organic sales increased 3% in the quarter, as a 5% increase in volume more than offset a 2% decline in price. The rise in volume was driven by sustained growth in the electronics market and a return of year-over-year growth in water solutions. DuPont saw continued semiconductor demand recovery in the quarter driven by AI technology applications and higher demand in China.Segment HighlightsThe company's Electronics & Industrial segment reported net sales of $1.55 billion in the quarter, a 13% year-over-year increase. Organic sales grew 10%, driven by an 11% rise in volume, which was modestly offset by a 1% decrease in price.The Water & Protection unit recorded net sales of $1.38 billion, a 2% decline from the previous year. The decline was due to a 2% drop in price with volumes remaining flat year over year.FinancialsDuPont had cash and cash equivalents of $1.65 billion at the end of the quarter, down around 9% sequentially. Long-term debt was $7.17 billion, flat sequentially.The company generated operating cash flow from continuing operations of $737 million in the third quarter.OutlookDuPont raised its projections for operating EBITDA and adjusted earnings per share. The company anticipates full-year 2024 net sales to be around $12.365 billion. Operating EBITDA is now forecast to be roughly $3.125 billion (up from the prior view of $3.060-$3.110 billion) while adjusted earnings are projected to be around $3.90 per share for the year (up from $3.70-$3.80 expected earlier).For the fourth quarter of 2024, DuPont forecasts net sales of around $3.070 billion, operating EBITDA of roughly $790 million and adjusted earnings of around 98 cents per share. The guidance assumes sales and earnings growth for both segments. The company expects normal seasonal declines in electronics and construction markets, partly offset by continued recovery in water and medical packaging markets.How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.VGM ScoresCurrently, DuPont de Nemours has an average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, DuPont de Nemours has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.Performance of an Industry PlayerDuPont de Nemours belongs to the Zacks Chemical - Diversified industry. Another stock from the same industry, Chemours (CC), has gained 2.7% over the past month. More than a month has passed since the company reported results for the quarter ended September 2024.Chemours reported revenues of $1.5 billion in the last reported quarter, representing a year-over-year change of +0.9%. EPS of $0.40 for the same period compares with $0.64 a year ago.Chemours is expected to post earnings of $0.30 per share for the current quarter, representing a year-over-year change of -3.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.5%.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Chemours. Also, the stock has a VGM Score of D.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DuPont de Nemours, Inc. (DD): Free Stock Analysis Report The Chemours Company (CC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf DuPont de Nemours
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DuPont de Nemours
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu DuPont de Nemours
Analysen zu DuPont de Nemours
Datum | Rating | Analyst | |
---|---|---|---|
04.10.2021 | DuPont de Nemours Overweight | JP Morgan Chase & Co. | |
20.08.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
25.06.2019 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
10.06.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
06.02.2019 | DowDuPont Market Perform | Cowen and Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
04.10.2021 | DuPont de Nemours Overweight | JP Morgan Chase & Co. | |
20.08.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
10.06.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
12.10.2018 | DowDuPont buy | Deutsche Bank AG | |
29.03.2018 | DowDuPont Outperform | BMO Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
25.06.2019 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
06.02.2019 | DowDuPont Market Perform | Cowen and Company, LLC | |
12.09.2017 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
31.05.2017 | Dow Chemical Market Perform | Cowen and Company, LLC | |
26.04.2017 | DuPont (E I DuPont de Nemours and Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
05.01.2009 | Dow Chemical verkaufen | Euro am Sonntag | |
11.04.2007 | Dow Chemical verkaufen | Hamburger Sparkasse | |
03.02.2006 | Update Rohm and Haas Co.: Reduce | UBS | |
07.07.2005 | Update Rohm and Haas Co.: Sell | Longbow |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DuPont de Nemours nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen